Skip to main content

New Additions to Drugs.com for 2022

We update the Drugs.com database on a regular cycle. The following new drug information was added in 2022:

Mounjaro
May 17, 2022 - Mounjaro (tirzepatide) is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes mellitus in adults.

Camzyos
Apr 30, 2022 - Camzyos (mavacamten) is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy.

Vivjoa
Apr 29, 2022 - Vivjoa (oteseconazole) is an oral azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis.

Epsolay
Apr 27, 2022 - Epsolay (benzoyl peroxide) is a topical oxidizing agent for the treatment of inflammatory lesions of rosacea in adults.

Pluvicto
Apr 13, 2022 - Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent indicated for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

Vijoice
Apr 7, 2022 - Vijoice (alpelisib) is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.

Hyftor
Apr 5, 2022 - Hyftor (sirolimus topical gel) is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis.

Tlando
Mar 30, 2022 - Tlando (testosterone) is an oral testosterone replacement therapy indicated for adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.

Xelstrym
Mar 24, 2022 - Xelstrym (dextroamphetamine) transdermal system is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and children 6 years and older.

Ztalmy
Mar 21, 2022 - Ztalmy (ganaxolone) is neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).

Opdualag
Mar 21, 2022 - Opdualag (nivolumab and relatlimab-rmbw) is programmed death receptor-1 (PD-1) blocking antibody and lymphocyte activation gene-3 (LAG-3) blocking antibody combination indicated for the treatment of unresectable or metastatic melanoma.

Adlarity
Mar 14, 2022 - Adlarity (donepezil transdermal system) is a once-weekly transdermal formulation of the approved acetylcholinesterase inhibitor donepezil indicated for the treatment of Alzheimer’s type dementia.

Carvykti
Mar 14, 2022 - Carvykti (ciltacabtagene autoleucel) is a BCMA-directed CAR-T immunotherapy for the treatment of patients with relapsed or refractory multiple myeloma.

Vonjo
Mar 7, 2022 - Vonjo (pacritinib) is a JAK2/FLT3 multikinase inhibitor for the treatment of myelofibrosis patients with severe thrombocytopenia.

Bebtelovimab
Feb 23, 2022 - Bebtelovimab is a monoclonal antibody (mAb) for use under EUA in certain non-hospitalized patients with mild-to-moderate COVID-19.

Pyrukynd
Feb 18, 2022 - Pyrukynd (mitapivat) is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Spikevax
Feb 9, 2022 - Spikevax (COVID-19 Vaccine, mRNA) is a COVID-19 vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Spikevax (Moderna COVID-19 Vaccine)
Feb 9, 2022 - Spikevax (COVID-19 Vaccine, mRNA) is a COVID-19 vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Enjaymo
Feb 7, 2022 - Enjaymo (sutimlimab-jome) is a classical complement inhibitor indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD).

Kimmtrak
Jan 31, 2022 - Kimmtrak (tebentafusp-tebn) is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Ryaltris
Jan 20, 2022 - Ryaltris (mometasone and olopatadine) nasal spray is a corticosteroid and antihistamine combination for the treatment of seasonal allergic rhinitis (SAR) in patients 12 years of age and older.

Cibinqo
Jan 18, 2022 - Cibinqo (abrocitinib) is a Janus kinase (JAK) 1 inhibitor for the treatment of adults with refractory, moderate-to-severe atopic dermatitis.

Quviviq
Jan 13, 2022 - Quviviq (daridorexant) is a dual orexin receptor antagonist (DORA) for the treatment of insomnia.

Browse additions by year: